LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.

Published in: Brain and behavior (2020)

LCIG provides an uninterrupted intestinal levodopa infusion by percutaneous endoscopic gastrojejunostomy (PEG-J). It effectively decreases plasma fluctuations of levodopa and reduces motor instability and NMS burden in advanced PD. However, adequate dose modification and individualization of therapy are essential for optimal effect.

Keyphrases

parkinson disease
ultrasound guided
deep brain stimulation
low dose
drug delivery
minimally invasive
stem cells
sleep quality
direct oral anticoagulants
depressive symptoms
bone marrow
venous thromboembolism